XRP2 Stock Overview
A biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Silence Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.00 |
| 52 Week High | US$26.80 |
| 52 Week Low | US$4.48 |
| Beta | 1.37 |
| 1 Month Change | -5.66% |
| 3 Month Change | -14.53% |
| 1 Year Change | 292.16% |
| 3 Year Change | -5.66% |
| 5 Year Change | n/a |
| Change since IPO | 26.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| XRP2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.9% | -1.3% | 0.1% |
| 1Y | 292.2% | -36.2% | 9.1% |
Return vs Industry: XRP2 exceeded the German Biotechs industry which returned -36.2% over the past year.
Return vs Market: XRP2 exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| XRP2 volatility | |
|---|---|
| XRP2 Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: XRP2's share price has been volatile over the past 3 months.
Volatility Over Time: XRP2's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 109 | Craig Tooman | www.silence-therapeutics.com |
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company’s mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera.
Silence Therapeutics plc Fundamentals Summary
| XRP2 fundamental statistics | |
|---|---|
| Market cap | €938.82m |
| Earnings (TTM) | -€41.04m |
| Revenue (TTM) | €31.02m |
30.3x
P/S Ratio-22.9x
P/E RatioIs XRP2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XRP2 income statement (TTM) | |
|---|---|
| Revenue | UK£26.41m |
| Cost of Revenue | UK£8.00m |
| Gross Profit | UK£18.41m |
| Other Expenses | UK£53.35m |
| Earnings | -UK£34.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 69.72% |
| Net Profit Margin | -132.31% |
| Debt/Equity Ratio | 0% |
How did XRP2 perform over the long term?
See historical performance and comparison